PIA
SLDB icon

Piedmont Investment Advisors’s Solid Biosciences SLDB Stock Holding History

Piedmont Investment Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11
Closed -$6K – 2078
2018
Q2 		$6K Buy
+11
New +$3.38K ﹤0.01% 2047

Other funds holding SLDB

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Piedmont Investment Advisors's SLDB Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Solid Biosciences (SLDB) in Q3 2018, closing a stake of 11 shares — an estimated $6K sold.

Piedmont Investment Advisors first reported a position in SLDB in Q2 2018 and held it in 1 quarter. The position peaked at $6K in Q2 2018. 76 funds tracked by Wall St. Rank hold SLDB as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Solid Biosciences position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 11 Solid Biosciences shares in Q3 2018, an estimated $6K.
  • Piedmont Investment Advisors first reported a position in Solid Biosciences in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Solid Biosciences position peaked at $6K in Q2 2018.
  • 76 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.